Asuragen Financial Conflict of Interest Policy
Asuragen is committed to preserving the public’s trust that the publicly funded research performed by Asuragen is conducted without bias and with the highest scientific and ethical standards. As part of that commitment and consistent with Asuragen Core Values and Code of Conduct, Asuragen expects that researchers will perform their research without bias resulting from financial conflicts of interest. To support that commitment and in compliance with the regulations encoded in 42 CFR Part 50 and 45 CFR Part 94, Asuragen has established this policy and supporting procedures to identify, mitigate, and report on financial conflicts of interest (FCOI) by investigators engaged in research funded by the Public Health Service (PHS).
Each investigator is required to disclose significant financial interests (SFI) related to their institutional responsibilities at the time of application for PHS-funded research and at least annually during the award periods or within 30 days of discovering or acquiring a new SFI, as defined in 42CFR§ 50.603. Disclosure of SFI is performed according to procedures outlined in Asuragen FCOI Procedures and consistent with 42CFR§ 50.604. Significant Financial Interests will be reviewed by the appointed Institutional Official to determine whether a FCOI exists and will establish a management plan and monitor investigator compliance until completion of the associated project. Asuragen will report any identified FCOI and management plans as required in 42CFR§ 50.605. Asuragen will train investigators regarding FCOI policy and responsibilities at the commencement of employment and/or prior to engaging in PHS-funded research and provide periodic training as necessary when Asuragen’s FCOI Policy or Procedures are revised, when non-compliances are identified.